NAD+ Metabolism

NAD+ & Aging: Why Levels Decline With Age

Written by ReCellence™ Editorial Team, Health Content SpecialistsReviewed by Medical Review Board, MD, PhDLast reviewed: March 8, 2026

Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.

What This Page Explains

NAD+ levels decline significantly with age — by approximately 50% between ages 40 and 60 in some tissues. This decline is now recognized as a hallmark of aging and a potential driver of age-related metabolic dysfunction.

Your Mitochondria Don't Know You're Reading This. But They Need You To.

They're working overtime with depleted NAD+, accumulated damage, and failing quality control. Help is one click away.

Detailed Evidence

Three primary mechanisms drive age-related NAD+ decline: (1) Increased CD38 expression — CD38 is an NADase that degrades NAD+, and its expression rises with chronic inflammation (inflammaging); (2) PARP hyperactivation — accumulated DNA damage with age triggers PARP-mediated NAD+ consumption; (3) Reduced NAMPT expression — the rate-limiting enzyme in the salvage pathway declines with age, reducing NAD+ recycling.

Evidence Hierarchy

Strongest

Systematic Reviews & Meta-Analyses

Multiple high-quality trials combined

Strong

Randomized Controlled Trials (RCTs)

Gold standard for treatment efficacy

Moderate

Observational Studies

Can show associations, not causation

Limited

Case Reports & Expert Opinion

Hypothesis-generating only

Weakest

Preclinical (Lab/Animal) Studies

Should NOT be extrapolated to humans

How to Stop Subsidizing Your Own Decline

Every day without mitochondrial support, you're paying a tax in energy, clarity, and vitality. Here's how to stop the hemorrhage.

Study Quality Indicators

Higher Quality Indicators

  • Large sample size (hundreds to thousands)
  • Randomized and blinded design
  • Placebo-controlled comparison
  • Published in peer-reviewed journals
  • Replicated in multiple studies
  • Registered trial protocol before starting

Lower Quality Indicators

  • Small sample size (under 100)
  • No control group or blinding
  • Manufacturer-funded with conflicts
  • Only animal/cell studies
  • Never replicated
  • Published in predatory journals

Important Limitations

  • • Supplement research often has methodological limitations
  • • Results from one study may not generalize to all people
  • • Marketing claims often exceed what research supports
  • • Absence of evidence is not evidence of absence
  • • Individual response to supplements varies widely

Quick Answers

Q1.

How much does NAD+ decline with age?

NAD+ levels fall by roughly 50% between ages 40 and 60 across several human tissues, with continued decline thereafter.

Q2.

What causes NAD+ to decline with age?

Three main drivers: rising CD38 activity from inflammation, PARP hyperactivation from accumulated DNA damage, and reduced NAMPT expression that slows salvage-pathway recycling.

Q3.

What is CD38 and why does it matter for aging?

CD38 is an NAD+-degrading enzyme (NADase) whose expression rises 2–3 fold with age and chronic inflammation, making it the dominant contributor to age-related NAD+ depletion.

Q4.

Does NAD+ decline cause aging or result from aging?

It is likely bidirectional — NAD+ decline both results from aging processes (inflammation, DNA damage) and actively drives further aging by impairing mitochondrial and repair functions.

Q5.

What is the pseudohypoxic state caused by NAD+ decline?

Low NAD+ reduces SIRT1 activity, disrupting the HIF-1α axis so cells behave as if oxygen-deprived (pseudohypoxia), impairing mitochondrial function despite normal oxygen.

Q6.

How does inflammation drive NAD+ depletion?

Inflammatory cytokines and senescent-cell SASP factors induce CD38 expression, which degrades NAD+ — a feed-forward loop that accelerates depletion.

Q7.

At what age does NAD+ start declining?

Measurable declines begin around the 30s–40s and accelerate through midlife, dropping substantially by age 60.

Q8.

Can NAD+ decline be reversed?

In animal studies, precursors like NMN and NR restore NAD+ and some functions; human trials confirm raised blood NAD+, with functional benefits still under investigation.

Q9.

How does PARP activation contribute to NAD+ decline?

PARP1 uses NAD+ to repair DNA damage; accumulated DNA damage with age causes PARP hyperactivation, consuming large amounts of NAD+.

Q10.

What tissues are most affected by NAD+ decline?

Skeletal muscle, liver, brain, and adipose tissue are particularly sensitive because of their high metabolic demand and dependence on NAD+-dependent repair.

Q11.

Is NAD+ decline a hallmark of aging?

NAD+ decline intersects with at least 5 of the 12 recognized hallmarks of aging, including mitochondrial dysfunction, cellular senescence, and genomic instability.

Q12.

How does NAD+ decline affect stem cells?

Lower NAD+ impairs sirtuin activity needed for stem cell maintenance; restoring NAD+ in aged mice revived muscle stem cell function and regeneration.

Q13.

What role does NAMPT play in age-related NAD+ decline?

NAMPT is the rate-limiting enzyme of the salvage pathway; its expression falls with age, reducing the cell's ability to recycle nicotinamide back into NAD+.

Q14.

Does obesity accelerate NAD+ decline?

Yes — obesity raises CD38 expression and lowers NAMPT activity, speeding NAD+ depletion and contributing to metabolic dysfunction.

Q15.

Are there sex differences in NAD+ decline?

Some evidence suggests NAD+ metabolism differs by sex and hormonal status (e.g., estrogen's mitochondrial effects), though most findings come from animal models.

Key Research Facts

1

NAD+ levels decline approximately 50% between ages 40 and 60 across multiple human tissues.

Strong Evidence

Massudi H et al., PLoS One — doi:10.1371/journal.pone.0042357

2

CD38 expression increases 2–3 fold with age and is the dominant driver of NAD+ depletion, exceeding PARP and sirtuin consumption combined.

Strong Evidence

Camacho-Pereira J et al., Cell Metab — doi:10.1016/j.cmet.2016.05.006

3

CD38 knockout mice are protected from age-related NAD+ decline and maintain youthful mitochondrial function.

Strong Evidence

Camacho-Pereira J et al., Cell Metab — doi:10.1016/j.cmet.2016.05.006

4

Age-related NAD+ decline creates a pseudohypoxic state through SIRT1/HIF-1α axis disruption.

Strong Evidence

Gomes AP et al., Cell — doi:10.1016/j.cell.2013.11.037

5

Senescent cell-derived SASP factors induce CD38 expression in neighboring cells, creating a feed-forward NAD+ depletion loop.

Strong Evidence

Chini CCS et al., Nat Metab — doi:10.1038/s42255-020-00298-z

6

PARP1 hyperactivation from accumulated DNA damage is the second largest contributor to age-related NAD+ consumption.

Strong Evidence

Fang EF et al., Cell Metab — doi:10.1016/j.cmet.2016.05.024

7

NAMPT expression decreases with age across multiple tissues, reducing salvage pathway capacity for NAD+ regeneration.

Strong Evidence

Revollo JR et al., J Biol Chem — doi:10.1074/jbc.M408168200

8

NMN supplementation restored muscle stem cell function and regenerative capacity in aged mice.

Strong Evidence

Zhang H et al., Science — doi:10.1126/science.aaf2693

9

Obesity accelerates NAD+ decline through increased CD38 expression and reduced NAMPT activity.

Strong Evidence

Yoshino J et al., Cell Metab — doi:10.1016/j.cmet.2011.08.014

10

NAD+ decline intersects with at least 5 of the 12 recognized hallmarks of aging.

Strong Evidence

López-Otín C et al., Cell — doi:10.1016/j.cell.2022.11.001

Continue Your Research

Explore related topics and take the next step in your cellular health journey.

Citations & External Resources

Review

Nature Reviews — NAD+ decline in aging

Review

Nature Metabolism — CD38 and NAD+ depletion

Review

Cell — Pseudohypoxic state from NAD+ decline

Review

NIH — NAD+ and hallmarks of aging

Review

Trends in Pharmacological Sciences — CD38 as NADase

Review

PLoS One — NAD+ decline in human tissues

Warning: This Is Not Another 'Miracle Supplement' Pitch

This is cellular science. Five research-backed compounds targeting five distinct mechanisms of aging. No miracles. Just biology.

Related Reading

References (4)

Written by

ReCellence™ Editorial Team

Health Content Specialists

Medically reviewed by

Medical Review Board

MD, PhD

Last updated: March 8, 2026

Last medical review: March 8, 2026